Literature DB >> 3549032

Diagnosis and management of prolactinomas.

J R Dollar, R E Blackwell.   

Abstract

Prolactin secreting tumors account for ten to twenty percent of all intracranial lesions. The patients harboring these tumors present with amenorrhea, galactorrhea, other ovulatory disorders, infertility, delays in puberty and mixed polyendocrinopathy. These tumors are diagnosed by the measurement of serum prolactin levels, Goldmann-Bowl perimetry, and either computed axial tomography or magnetic resonance imaging. Protein secreting tumors are usually benign lesions and historically have been treated by partial or total hypophysectomy or radiation therapy. Surgical resection of the lesion often is followed by recurrence and administration of proton beam radiation therapy results in the development of a panhypopituitary state. Growth of pituitary tumors is controlled with the administration of dopamine agonists such as bromocriptine and prospective studies have suggested that these drugs are now the preferred method of treatment for primary lesions and recurrences.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3549032     DOI: 10.1007/BF00046427

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  38 in total

Review 1.  Prolactin secreting pituitary adenomas in women with amenorrhea or galactorrhea.

Authors:  W R Keye; R J Chang; R B Jaffe
Journal:  Obstet Gynecol Surv       Date:  1977-11       Impact factor: 2.347

2.  Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series.

Authors:  G N Burrow; G Wortzman; N B Rewcastle; R C Holgate; K Kovacs
Journal:  N Engl J Med       Date:  1981-01-15       Impact factor: 91.245

3.  The incidence of complications during pregnancy after treatment of hyperprolactinemia with bromocriptine in patients with radiologically evident pituitary tumors.

Authors:  S W Lamberts; J G Klijn; S A de Lange; R Singh; S Z Stefanko; J C Birkenhäger
Journal:  Fertil Steril       Date:  1979-06       Impact factor: 7.329

4.  Defective regulation of prolactin secretion after successful removal of prolactinomas.

Authors:  F Camanni; E Ghigo; E Ciccarelli; F Massara; C Campagnoli; G Molinatti; E E Müller
Journal:  J Clin Endocrinol Metab       Date:  1983-12       Impact factor: 5.958

5.  Successful outcome of ergocryptine-induced pregnancies in twenty-one women with prolactin-secreting pituitary adenomas.

Authors:  B Corenblum
Journal:  Fertil Steril       Date:  1979-08       Impact factor: 7.329

6.  Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study.

Authors:  M Bassetti; A Spada; G Pezzo; G Giannattasio
Journal:  J Clin Endocrinol Metab       Date:  1984-02       Impact factor: 5.958

7.  Dopamine infusion studies in patients with pathological hyperprolactinemia: evidence of normal prolactin suppressibility but abnormal dopamine metabolism.

Authors:  K Y Ho; G A Smythe; M Duncan; L Lazarus
Journal:  J Clin Endocrinol Metab       Date:  1984-01       Impact factor: 5.958

8.  Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study.

Authors:  M E Molitch; R L Elton; R E Blackwell; B Caldwell; R J Chang; R Jaffe; G Joplin; R J Robbins; J Tyson; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1985-04       Impact factor: 5.958

9.  Visual field defects and pituitary enlargement in primary hypothyroidism.

Authors:  K Yamamoto; K Saito; T Takai; M Naito; S Yoshida
Journal:  J Clin Endocrinol Metab       Date:  1983-08       Impact factor: 5.958

10.  Ocular manifestations of pituitary adenomas.

Authors:  A A Halle; R D Drewry; J T Robertson
Journal:  South Med J       Date:  1983-06       Impact factor: 0.954

View more
  4 in total

1.  Quinagolide in the management of prolactinoma.

Authors:  P N Schultz; L Ginsberg; I E McCutcheon; N Samaan; M Leavens; R F Gagel
Journal:  Pituitary       Date:  2000-12       Impact factor: 4.107

2.  Quantitative Evaluation of Pupil Responses in Patients with Prolactinomas Being Treated with Dopamine Agonists.

Authors:  Sedat Ava; Leyla Hazar; Mine Karahan; Seyfettin Erdem; Mehmet Emin Dursun; Zafer Pekkolay; Uğur Keklikçi
Journal:  Neuroophthalmology       Date:  2022-01-25

3.  PET studies with L-[1-11C]tyrosine, L-[methyl-11C]methionine and 18F-fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment.

Authors:  B J Daemen; R Zwertbroek; P H Elsinga; A M Paans; H Doorenbos; W Vaalburg
Journal:  Eur J Nucl Med       Date:  1991

4.  Nonsurgical treatment of male infertility: specific and empiric therapy.

Authors:  Marcello Cocuzza; Ashok Agarwal
Journal:  Biologics       Date:  2007-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.